Logo

Empire Genomics Licenses Roswell Park's Genomics Libraries, Accesses Labs, Personnel

Jul 16, 2007
NEW YORK (GenomeWeb News) — Empire Genomics has licensed Roswell Park Cancer Institute’s genomic libraries, and will temporarily use its laboratory space, equipment, and expertise, RPCI said today.
 
Empire Genomics, a spin-out of RPCI and the University of Buffalo that offers human and mouse BAC microarrays, is developing a prenatal and postnatal diagnostic array using RPCI’s genomic libraries that will test for 100 different microdeletions, including those linked to various diseases.
 
Empire President and CEO Anthony Johnson said the company expects to continue to operate out of RPCI’s labs for around a year, and then to move into new facilities on the Buffalo Niagara Medical Campus, near the RPCI.
 
Johnson said the company expects to hire as many as 60 new staffers over the next five years.
 
Financial terms of the agreement were not released.

Breaking News
The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.